NCT05365568

Brief Summary

The aim of this study proposal is to compare the effectiveness of two distinct pacing modalities for cardiac resynchronization therapy. Our primary hypothesis is that left bundle branch area pacing (LBBAP) using conventional stylet driven pacemaker leads is an effective resynchronization method that yield to at least similar clinical benefits and outcomes when compare to biventricular pacing.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
170

participants targeted

Target at P75+ for not_applicable

Timeline
29mo left

Started Sep 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

11 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress61%
Sep 2022Sep 2028

First Submitted

Initial submission to the registry

April 29, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 9, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2028

Expected
Last Updated

September 23, 2024

Status Verified

September 1, 2024

Enrollment Period

3.1 years

First QC Date

April 29, 2022

Last Update Submit

September 20, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of days elapsed from study procedure to first occurrence of one of the following events (combined endpoint) or to study close-out in the total patient population.

    First occurrence of one of the following clinical events: death, hospitalization or unscheduled visit for heart failure (HF) or worsening HF symptoms with adaptation of the medical therapy, implant failure for any cause, implantable electronic cardiac device (IECD) re-intervention for any reason during follow-up (Lead Dislocation/phrenic nerve stimulation…)

    12 months

Secondary Outcomes (5)

  • Improvement of procedural characteristics: Operative and fluoroscopic times

    1 day

  • Correction of electrical desynchrony post-implant

    1/6/12 months

  • Clinical functional response (6MWT)

    6 months

  • Left ventricular reverse remodelling

    6/12 months

  • Implantable cardioverter defibrillator (ICD) therapies

    6/12 months

Study Arms (2)

LBBAP

EXPERIMENTAL
Procedure: Left Bundle Branch Area Pacing (LBBAP)

BiV

ACTIVE COMPARATOR
Procedure: Biventricular pacing (BiV)

Interventions

Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy

LBBAP

Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)

BiV

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18 or above
  • Left Ventricular Ejection Fraction (LVEF) and NYHA meeting one off the previous indications documented with transthoracic echocardiography (TTE) no later than 3 months before randomization.
  • New York Heart Association (NYHA) class II-IV
  • Baseline left bundle branch block and QRS \>130ms or QRS \>150ms of any morphology or a wide paced QRS duration.

You may not qualify if:

  • Younger than 18 years old
  • Pregnancy
  • Any unstable medical condition, life expectancy \< 12 months
  • Inability to provide consent or to undergo follow-up
  • Narrow QRS duration (≤130ms) or prolonged QRS duration with typical Right Bundle Branch Block (RBBB) morphology on 12 lead ECG and sinus rhythm.
  • Significant hypertrophic cardiomyopathy - any septum abnormality contra-indicating LBBAP implantation (according to physician's evaluation)
  • Patients who are unable to perform a 6 minute walk test (6MWT) Note: patients should be able to perform a 6 minute walk test, but it is not a requirement to have the test performed before the procedure (e.g. due to inability of planning).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

UZA

Edegem, Antwerpen, 2650, Belgium

Location

CHU Charleroi

Lodelinsart, Henegouwen, 6042, Belgium

Location

Jessa Ziekenhuis Hasselt

Hasselt, Limburg, 3500, Belgium

Location

CHR Citadelle Liège

Liège, Liège, 4000, Belgium

Location

UZ Gent

Ghent, Oost-Vlaanderen, 9000, Belgium

Location

UZ Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Location

UCL Saint-Luc

Woluwe-Saint-Lambert, Vlaams-Brabant, 1200, Belgium

Location

Clinique Saint-Pierre Ottignies

Ottignies-Louvain-la-Neuve, Waals-Brabant, 1340, Belgium

Location

AZ Sint-Jan Brugge

Bruges, West-Vlaanderen, 8000, Belgium

Location

AZ Delta

Roeselare, West-Vlaanderen, 8800, Belgium

Location

CHU HELORA - Site Jolimont

Haine-Saint-Paul, 7100, Belgium

Location

MeSH Terms

Interventions

Cardiac Resynchronization Therapy

Intervention Hierarchy (Ancestors)

Cardiac Pacing, ArtificialElectric Stimulation TherapyTherapeutics

Study Officials

  • Jean-Benoît le Polain de Waroux, MD, PhD

    AZ Sint Jan Brugge AV

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Coordinating Principal Investigator

Study Record Dates

First Submitted

April 29, 2022

First Posted

May 9, 2022

Study Start

September 1, 2022

Primary Completion

September 30, 2025

Study Completion (Estimated)

September 30, 2028

Last Updated

September 23, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations